W. EDMUND FARRAR, M.D.
This content is PDF only. Please click on the PDF icon to access.
Twelve years ago Lund and Tybring (1) described a new antibiotic, amdinocillin (mecillinam), an amidinopenicillin that differs significantly from conventional penicillins and cephalosporins in the nature of the bond between the side chain and the nitrogen attached at the 6-position of the beta-lactam ring (Figure 1). This agent is likely to be released for clinical use in the United States in the near future.
From the clinician's point of view, the chief interest of amdinocillin lies in its high degree of activity against many species of enteric gram-negative bacilli, including Escherichia coli, Salmonella, Shigella, Citrobacter, Enterobacter, Klebsiella, Proteus, and Serratia
FARRAR WE. Amdinocillin. Ann Intern Med. 1984;101:389–390. doi: 10.7326/0003-4819-101-3-389
Download citation file:
Published: Ann Intern Med. 1984;101(3):389-390.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use